標(biāo)題: Titlebook: Dose Finding in Drug Development; Naitee Ting Book 2006 Springer-Verlag New York 2006 Maxima.Radiologieinformationssystem.clinical trial.c [打印本頁] 作者: 諷刺文章 時間: 2025-3-21 16:38
書目名稱Dose Finding in Drug Development影響因子(影響力)
書目名稱Dose Finding in Drug Development影響因子(影響力)學(xué)科排名
書目名稱Dose Finding in Drug Development網(wǎng)絡(luò)公開度
書目名稱Dose Finding in Drug Development網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Dose Finding in Drug Development被引頻次
書目名稱Dose Finding in Drug Development被引頻次學(xué)科排名
書目名稱Dose Finding in Drug Development年度引用
書目名稱Dose Finding in Drug Development年度引用學(xué)科排名
書目名稱Dose Finding in Drug Development讀者反饋
書目名稱Dose Finding in Drug Development讀者反饋學(xué)科排名
作者: 曲解 時間: 2025-3-21 20:18
1431-8776 iewers from Food and Drug Administration (FDA) review these documents and make a decision to approve or to reject this New Drug Application (NDA). If the new drug is approved, then Phase IV studies can be start978-1-4419-2115-4978-0-387-33706-7Series ISSN 1431-8776 Series E-ISSN 2197-5671 作者: HOWL 時間: 2025-3-22 02:35 作者: 衰弱的心 時間: 2025-3-22 05:54
Ultrasonography in Ophthalmology XVThe . . model is a nonlinear model frequently used in dose–response analyses. The model is shown in Eq. (9.1)作者: 名字的誤用 時間: 2025-3-22 11:21 作者: 胎兒 時間: 2025-3-22 14:44
,Analysis of Dose–Response Studies—Emax Model,The . . model is a nonlinear model frequently used in dose–response analyses. The model is shown in Eq. (9.1)作者: 胎兒 時間: 2025-3-22 20:24
Introduction and New Drug Development Process,the intended disease condition) and safe (with acceptable risk of adverse effects). If such a dose range cannot be identified, the candidate would not be a medically useful or commercially viable pharmaceutical product, nor should it be approved by regulatory agencies.作者: uveitis 時間: 2025-3-22 23:02 作者: 使人入神 時間: 2025-3-23 03:21
Boolean Algebras and Propositional Calculusthe intended disease condition) and safe (with acceptable risk of adverse effects). If such a dose range cannot be identified, the candidate would not be a medically useful or commercially viable pharmaceutical product, nor should it be approved by regulatory agencies.作者: 公司 時間: 2025-3-23 06:41
https://doi.org/10.1007/978-94-011-5040-8ied from a cell culture or from a modified animal or egg. There is often some biological theory that supports the creation of this candidate. It might be based upon inserting a specific human gene into the DNA of the culture, or some specific configuration of the small molecule that is designed to “作者: multiply 時間: 2025-3-23 13:17
D. Graham Holmes,Christopher B. Lorenceients experiencing adverse events (AEs) unnecessarily (Herxheimer, 1991; ICH-E4, 1994). Over the last 5 years, a greater effort has been made to ensure that the best benefit to risk assessment is obtained for each new drug (Andrews and Dombeck, 2004; Bush et al., 2005). The benefit to risk assessmen作者: DECRY 時間: 2025-3-23 13:59
Wolfgang H?hn,Torsten H. Franssonimately 10% mortality (the murine LD.). One-tenth or two-tenths of the murine equivalent of LD., expressed in milligrams per meters squared, is usually used as a starting dose in a Phase I trial. It is standard to choose a set of doses according to the modified Fibonacci sequence in which higher esc作者: BAIL 時間: 2025-3-23 20:49 作者: Expertise 時間: 2025-3-23 23:35 作者: 輕快走過 時間: 2025-3-24 02:34 作者: 琺瑯 時間: 2025-3-24 10:13 作者: single 時間: 2025-3-24 13:29 作者: micturition 時間: 2025-3-24 16:29
The Songs of Bush Crickets (Tettigoniidae),nse relationships. On the other hand, Phase III studies are designed to confirm findings from early phases, and results from Phase III studies are used for submission to regulatory agencies for drug approval. Hence, Phase III studies are designed for decision making. In terms of hypotheses testing, 作者: 火花 時間: 2025-3-24 20:35
Gegenseitige Lage von Geraden und Ebenen,the world was to describe complicated phenomena using simple categories. Thus, it is hardly surprising that medical researchers often seek to categorize data in their attempt to make sense of unfamiliar measurement scales and treatment effects of uncertain implication. For this reason, threshold val作者: PLAYS 時間: 2025-3-25 02:44
https://doi.org/10.1007/978-94-011-9597-3nitial introduction of an investigational new drug in humans. The primary objectives are to (1) determine the metabolism and pharmacological activities of the drug, the side effects associated with increasing dose and early evidence in effectiveness and (2) obtain sufficient information regarding th作者: abolish 時間: 2025-3-25 05:36
Naitee TingIntroduces the drug development process, the design and analysis of clinical trials.Presents statistical applications in the design and analysis of dose response studies.Examines important procedural 作者: 類似思想 時間: 2025-3-25 10:02
Statistics for Biology and Healthhttp://image.papertrans.cn/e/image/282677.jpg作者: 舔食 時間: 2025-3-25 15:42
https://doi.org/10.1007/0-387-33706-7Maxima; Radiologieinformationssystem; clinical trial; computerassistierte Detektion; development; drug; dr作者: 自制 時間: 2025-3-25 17:36
978-1-4419-2115-4Springer-Verlag New York 2006作者: Debrief 時間: 2025-3-25 23:58 作者: 彎曲道理 時間: 2025-3-26 03:15 作者: 獸群 時間: 2025-3-26 06:13
Regas Santas,A. Koussoulaki,D.-P. H?dercal studies are designed and carried out according to this plan, and the CDP is updated over time based on newly available information. Estimation of dose–response relationship should be one of the very important components in CDP.作者: 易于交談 時間: 2025-3-26 12:12 作者: RAG 時間: 2025-3-26 15:09 作者: 歌曲 時間: 2025-3-26 19:04 作者: amyloid 時間: 2025-3-26 21:35 作者: 贊美者 時間: 2025-3-27 02:53
D. Graham Holmes,Christopher B. Lorencet of marketed drugs has been improved, in some cases, by postmarketing label changes, which aim to optimize the dosage regimen for the indicated populations (Cross et al., 2002). These postmarketing changes in the label may reflect the quality of drug development, regulatory review and postmarketing surveillance.作者: 誘使 時間: 2025-3-27 06:35
Wolfgang H?hn,Torsten H. Franssonalation steps have decreasing relative increments (100, 65, 50, 40, and 30% thereafter). Toxicity in oncology trials is graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (available online from the Cancer Therapy Evaluation Program website http://ctep.cancer.gov).作者: 同步左右 時間: 2025-3-27 13:04
Ultrasonography in Ophthalmology XVffect on the outcome under consideration, the so called proof-of-activity (PoA), sometimes also referred to as a proof-of-concept (PoC), and selecting a dose (or doses) that appears to be efficacious and safe, for further development in Phase III, the so-called dose-finding step.作者: extinguish 時間: 2025-3-27 16:32
The Songs of Bush Crickets (Tettigoniidae),ways of controlling the familywise error rate (FWER) strongly should be well specified prior to unmasking the study data. In many cases, these prespecification need to be clearly communicated with regulatory agencies for mutual agreement.作者: anus928 時間: 2025-3-27 20:48 作者: GULLY 時間: 2025-3-27 22:50
Martyn M. Caldwell,Stephan D. Flintls. This chapter describes how the dose–response relationship can be understood in pharmacological terms. It reviews the basic principles of clinical pharmacology (pharmacokinetics, pharmacodynamics, and disease progress) and shows how they can be used to describe the time course of response both with and without drug.作者: EWE 時間: 2025-3-28 05:27
https://doi.org/10.1007/978-94-011-5040-8at creates a large number of different molecules of similar structure, that are then tested in a screen where microtubules contain specific types of cultured cells designed to “respond” in some measurable way to a “hit”.作者: 終端 時間: 2025-3-28 09:18 作者: PUT 時間: 2025-3-28 12:53
https://doi.org/10.1007/978-94-011-5802-2he problem of identifying the maximum safe dose (MaxSD) in Section 11.3. Examples are given in Section 11.4 followed by some extensions in Section 11.5. The paper concludes with a discussion in Section 11.6.作者: 使增至最大 時間: 2025-3-28 17:45
https://doi.org/10.1007/978-94-011-9597-3, Phase I clinical investigation includes studies of drug metabolism, bioavailibility, dose ranging, and multiple dose. For doseescalation studies, clinical researchers usually start with lowdose which is unlikely to present any harmful effects to subjects.作者: CLAY 時間: 2025-3-28 19:04 作者: 良心 時間: 2025-3-29 00:12
,Dose Finding in Oncology—Parametric Methods,orresponds to the highest dose associated with a tolerable level of toxicity. More precisely, the MTD γ is defined as the dose expected to produce some degree of medically unacceptable, dose limiting toxicity (DLT) in a specified proportion θ of patients (see Gatsonis and Greenhouse, 1992). Hence, we have作者: 留戀 時間: 2025-3-29 05:17
Multiple Comparison Procedures in Dose Response Studies,he problem of identifying the maximum safe dose (MaxSD) in Section 11.3. Examples are given in Section 11.4 followed by some extensions in Section 11.5. The paper concludes with a discussion in Section 11.6.作者: CON 時間: 2025-3-29 09:28
Power and Sample Size for Dose Response Studies,, Phase I clinical investigation includes studies of drug metabolism, bioavailibility, dose ranging, and multiple dose. For doseescalation studies, clinical researchers usually start with lowdose which is unlikely to present any harmful effects to subjects.作者: 常到 時間: 2025-3-29 15:06
Dose-Finding Studies in Phase I and Estimation of Maximally Tolerated Dose,t of marketed drugs has been improved, in some cases, by postmarketing label changes, which aim to optimize the dosage regimen for the indicated populations (Cross et al., 2002). These postmarketing changes in the label may reflect the quality of drug development, regulatory review and postmarketing surveillance.作者: fastness 時間: 2025-3-29 18:13
,Dose-Finding in Oncology—Nonparametric Methods,alation steps have decreasing relative increments (100, 65, 50, 40, and 30% thereafter). Toxicity in oncology trials is graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (available online from the Cancer Therapy Evaluation Program website http://ctep.cancer.gov).作者: indemnify 時間: 2025-3-29 20:33
,Analysis of Dose–Response Studies—Modeling Approaches,ffect on the outcome under consideration, the so called proof-of-activity (PoA), sometimes also referred to as a proof-of-concept (PoC), and selecting a dose (or doses) that appears to be efficacious and safe, for further development in Phase III, the so-called dose-finding step.作者: deadlock 時間: 2025-3-30 01:07
,Partitioning Tests in Dose–Response Studies with Binary Outcomes,ways of controlling the familywise error rate (FWER) strongly should be well specified prior to unmasking the study data. In many cases, these prespecification need to be clearly communicated with regulatory agencies for mutual agreement.作者: 美學(xué) 時間: 2025-3-30 06:07 作者: 預(yù)知 時間: 2025-3-30 08:35
Dose Finding Based on Preclinical Studies,ied from a cell culture or from a modified animal or egg. There is often some biological theory that supports the creation of this candidate. It might be based upon inserting a specific human gene into the DNA of the culture, or some specific configuration of the small molecule that is designed to “
